SCHEMBL2500375

SCHEMBL2500375

CN(C)c1ccc(-c2nc(-c3ccc(O[Si](C)(C)C(C)(C)C)cc3)cnc2N)cc1

nearest known ligand 0.44

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ADK P55263 4/20 0.44
ATR Q13535 4/20 0.41
APP P05067 4/20 0.40
KCNH2 Q12809 3/20 0.38
PREP P48147 1/20 0.38
NEK2 P51955 1/20 0.37
TNK2 Q07912 1/20 0.37
NOS1 P29475 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2500547 0.92 KCNH2 (0.43) ATRKCNH2PREPNEK2
SCHEMBL2502121 0.87 ATR (0.49) ATRNEK2
SCHEMBL12198450 0.87 ATR (0.43) ATRKCNH2PREPNEK2
SCHEMBL2507103 0.81 PRKDC (0.42) ATRKCNH2NEK2
SCHEMBL2504524 0.81 RAB9A (0.43) ATRKCNH2PREPNEK2
SCHEMBL2506344 0.81 ATR (0.47) ADKATRKCNH2PREPNEK2
SCHEMBL23064155 0.80 PREP (0.42) ADKATRPREPNEK2NOS1
SCHEMBL15457713 0.79 ATR (0.38) ATRKCNH2PREPNEK2
SCHEMBL29903476 0.79 PREP (0.43) ATRPREPNEK2NOS1
SCHEMBL2506338 0.79 PREP (0.43) ATRPREPNEK2NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9075058-B2 Coelenterazine analogues and coelenteramide analogues JNC CORPORATION (JP) 2015-07-07 US disclosed
US-9056840-B2 Coelenterazine analogues and coelenteramide analogues JNC CORPORATION (JP) 2015-06-16 US disclosed
US-9056840-B2 Coelenterazine analogues and coelenteramide analogues JNC CORPORATION (JP) 2015-06-16 US disclosed
US-20150153344-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES JNC CORP (JP) 2015-06-04 US disclosed
US-20150153344-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES JNC CORP (JP) 2015-06-04 US disclosed
US-8883432-B2 Coelenterazine analogues and coelenteramide analogues JNC CORPORATION (JP) 2014-11-11 US disclosed
US-20140316137-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES JNC CORP (JP) 2014-10-23 US disclosed
US-20140316137-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES JNC CORP (JP) 2014-10-23 US disclosed
US-20140120538-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2014-05-01 US disclosed
US-8642281-B2 Coelenterazine analogues and coelenteramide analogues JNC CORPORATION (JP) 2014-02-04 US disclosed
US-20110244481-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES JNC CORPORATION (JP) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140120538-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES CCKAR, SI, GLP1R ADK 4099/4885ATR 4715/4885APP 3970/4885
US-20140316137-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES CCKAR, SI, GLP1R ADK 4095/4885ATR 4796/4885APP 4175/4885
US-20110244481-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES CCKAR, SI, GLP1R ADK 4099/4885ATR 4715/4885APP 3970/4885
US-20150153344-A1 COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES CCKAR, SI, GLP1R ADK 4099/4885ATR 4715/4885APP 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.